DICE Therapeutics is a biopharmaceutical company using its proprietary technology platform to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Co.'s platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions. Co.'s therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in various immunology indications. Co. is also developing oral therapeutic candidates for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. We show 4 historical shares outstanding datapoints in our coverage of DICE's shares outstanding history.
Understanding the changing numbers of DICE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like DICE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching DICE by allowing them to research DICE shares outstanding history
as well as any other stock in our coverage universe. |
Free DICE Email Alerts:
Video: Shares Outstanding Importance
